Prof Ray McDermott
M.B. B.Ch. B.A.O., Ph.D., M.B.A., F.R.C.P.I.
Clinical Professor in Medical Oncology, University College Dublin
Professor Ray McDermott commenced his training in Medical Oncology at the Mater Hospital, Dublin during which time he completed an MBA in Health Services Management. His thesis was circulated as a Working Paper through the Business School at University College Dublin, prior to publication in a peer reviewed management journal. From there, he went to the Institut Curie, Paris (2000-2002) where he earned a PhD in Tumour Immunology. He subsequently completed his clinical training at Fox Chase Cancer Center, Philadelphia (2002-2004), where he furthered an interest in Genito-Urinary Oncology. During this training period, he published over twenty peer reviewed articles and Book Chapters. He took up a post as Consultant Medical Oncologist at the Adelaide Meath & National Children’s Hospital, Tallaght in July 2004.
Under the leadership of Professor McDermott the Department of Medical Oncology at AMNCH was established and experienced a period of rapid growth. He established a Cancer Clinical Trials programme and currently over 10% of patients seen are enrolled on a clinical protocol, twice the national average. In 2006, Professor McDermott was instrumental in establishing Ireland as a main member of the Eastern Co-Operative Group, the largest clinical trials group in the USA. Professor McDermott is the Principal Investigator for Ireland in this initiative.
In 2009, Professor McDermott became Vice Clinical Lead of the Irish Clinical Oncology Research Group (rebranded as Cancer Trials Ireland in 2016). In 2012, he took over as Clinical Lead and facilitated an organisational restructure with appointment of an independent Board of Directors and development of a strategic vision for cancer trials in Ireland. He successfully led the grant renewal programme adjudicated upon by an independent panel appointed by the Health Research Board with an award of €9,000,000 over 3 years.
In 2010 under the auspices of the National Cancer Control Programme and the establishment of “Centres of Excellence”, Professor McDermott’s public hospital commitment was split between AMNCH and St Vincent’s University Hospital. He continues to pursue research interests in genito-urinary and pancreas cancer. Both the Irish Cancer Society and Movember have awarded him research grants in prostate cancer. He has also developed and run over 10 investigator initiated clinical and translational studies in prostate, renal, and pancreas cancers with associated funding of several million euros. He has been national co-ordinator on multiple clinical studies and is on the steering committee of many. He is currently accruing patients to over 20 studies across 2 sites ranging from Phase 1b to Phase 3.
In 2016, he was appointed Clinical Professor in Medical Oncology by University College Dublin. He is committed to improving outcomes for Irish patients with cancer through clinical and translational research. Along with Dr Jennifer Westrup, he has been involved in the establishment and growth of the cancer services at the Beacon Hospital.